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Extracellular vesicles (EVs) have great potential as biomarkers since their composition
and concentration in biofluids are disease state dependent and their cargo can contain
disease-related information. Large tumor-derived EVs (tdEVs, >1µm) in blood from
cancer patients are associated with poor outcome, and changes in their number can
be used to monitor therapy effectiveness. Whereas, small tumor-derived EVs (<1µm)
are likely to outnumber their larger counterparts, thereby offering better statistical
significance, identification and quantification of small tdEVs are more challenging. In
the blood of cancer patients, a subpopulation of EVs originate from tumor cells, but
these EVs are outnumbered by non-EV particles and EVs from other origin. In the
Dutch NWO Perspectief Cancer-ID program, we developed and evaluated detection
and characterization techniques to distinguish EVs from non-EV particles and other EVs.
Despite low signal amplitudes, we identified characteristics of these small tdEVs that
may enable the enumeration of small tdEVs and extract relevant information. The insights
obtained from Cancer-ID can help to explore the full potential of tdEVs in the clinic.
Keywords: atomic force microscopy, electrochemistry, electron microscopy, extracellular vesicles, flow
cytometry, fluorescence microscopy, Raman spectrum analysis, surface plasmon resonance imaging
INTRODUCTION
Extracellular vesicles (EVs) are cell-derived particles with a phospholipid membrane. Because
the membrane composition and content of EVs reflect the origin and state of the parental
cells, EVs have become promising disease biomarkers (1–4). Participants from eight universities
and 21 companies, who collaborate in the Dutch NWO Perspectief program Cancer-ID,
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aim to develop and evaluate technology to detect tumor-derived
EVs (tdEVs) in blood as biomarker for cancer.
Throughout the project, two main challenges involved in the
detection of EVs in blood became apparent. First, EV detection
is hampered because EVs are outnumbered by the presence of
non-EV particles in blood, like soluble proteins and lipoprotein
particles at the low end of the EV size and density range, and
platelets at the high end of the EV size and density range (5–
7). Moreover, the concentration of larger lipoproteins, such as
chylomicrons, depends on food intake, thereby emphasizing the
need to discriminate EVs from other such particles. To illustrate
this challenge, we determined that 1ml of human blood of
metastatic castration-resistant prostate cancer patients contains
about 10 large (>1µm) tdEVs (8, 9), and we extrapolated this
to encompass the small tdEVs to arrive at an estimated 104
tdEVs per 1ml. Furthermore, the blood contains up to 1016
lipoproteins, up to 109 platelets, and up to 1011 other EVs (5, 7,
10–12), see Figure 1. The second challenge is the heterogeneity
of EVs in many aspects, including morphology (13), size (13, 14),
membrane composition (8, 15–19), and refractive index (20, 21),
which complicates EV isolation, detection, and enumeration.
In sum, utilization of tdEVs as cancer biomarker requires
(i) the discrimination of EVs from non-EV particles, (ii)
identification of their cellular origin, and/or (iii) analysis of the
EV molecular content. The insight that an EV-based cancer
biomarker requires the ability to detect, identify, and enumerate
tdEVs among other particles’ plasma is an essential Cancer-
ID outcome because it defines the state-of-the-art. Therefore,
we will use this definition to evaluate the 10 techniques
that were developed or improved throughout the project.
The project includes techniques that (i) detect single particles
attached to a surface, such as atomic force microscopy (AFM),
electrochemical (EC) detection, scanning electron microscopy
(SEM), and transmission electron microscopy (TEM); (ii) detect
an ensemble of EVs attached to a surface, such as surface
plasmon resonance imaging (SPRi); (iii) detect single EVs
in suspension, such as flow cytometry (FCM); or (iv) can
measure either single or multiple EVs attached to a substrate
or in a suspension, such as Raman microspectroscopy. The
other evaluated technologies are integrated photonics lab-on-
chip devices for Raman spectroscopy, hybrid AFM–SEM–
Raman, and immunomagnetic epithelial cell adhesion molecule
(EpCAM) enrichment followed by fluorescence microscopic
(FM) detection. The evaluated techniques including key
characteristics are listed in Table 1. This table also gives an
estimate of tdEV throughput from each technique applied in a
clinical setting, taking into consideration the vast majority of
non-tdEV particles in plasma that may or may not contribute to
the signal.
To compare all techniques, EVs derived from prostate
cancer cell lines and EVs derived from platelet and red blood
cell concentrates were distributed among the participants and
measured. Based on the aforementioned requirements, we
aimed to qualify the ability of a technique to (i) detect or
image EVs, (ii) identify tdEVs, which involves differentiation
of tdEVs from EVs and non-EV particles, and (iii) relate
the measured signal or count to the concentration of tdEVs
in plasma.
PREPARATION OF EV SAMPLES
Two prostate cancer cell lines (PC3 and LNCaP) purchased
from the American Type Culture Collection (ATCC, Manassas,
VA) were used to obtain prostate-cancer-derived EVs. The cell
lines were cultured at 37◦C and 5% CO2 in Roswell Park
Memorial Institute (RPMI)-1640 with L-glutamine (Lonza, Basel,
Switzerland) supplemented with 10% v/v fetal bovine serum
(FBS) and 1% v/v penicillin and streptomycin (Lonza). Medium
was refreshed every second day. The initial cell density was 10,000
cells/cm2 as recommended by the ATCC. The cells were washed
three times with phosphate-buffered saline (PBS; Sigma, Saint
Louis, MO) when they reached 80–90% confluence. Next, FBS-
free RPMI medium supplemented with 0.1% v/v penicillin and
streptomycin was added to the cells. After 48 h of cell culture, the
cell supernatant was collected and centrifuged for 30min at 1,000
g. The supernatant was collected, and aliquots were snap frozen
in liquid nitrogen and stored at−80◦C.
Red blood cell concentrate (150ml) obtained from Sanquin
(Amsterdam, Netherlands) was diluted in a 1:1 ratio with
filtered PBS [154mM NaCl, 1.24mM Na2HPO4·2H2O, 0.2mM
NaH2PO4·2H2O, pH 7.4; 0.22µm filter (Merck Chemicals BV,
Darmstadt, Germany)] and centrifuged three times for 20min
at 1,560 g. Platelet concentrate (100ml) obtained from Sanquin
was diluted in a 1:1 ratio with filtered PBS. Next, 40ml acid
of citrate dextrose (ACD; 0.85M trisodiumcitrate, 0.11M D-
glucose, and 0.071M citric acid) was added, and the suspension
was centrifuged for 20min at 800 g. Thereafter, the supernatant
was centrifuged three times (20min at 1,560 g) to ensure removal
of platelets. The supernatant was collected, and aliquots of 50 µl
were snap frozen in liquid nitrogen and stored at−80◦C.
The particle size distributions of the EV samples were
obtained using nanoparticle tracking analysis (NTA NS500;
Nanosight, Amesbury, UK), equipped with an electron
multiplying charge-coupled device (EMCCD) camera and
a 405-nm diode laser (Figure 2A). Silica beads (105 nm;
Microspheres–Nanospheres, Cold Spring, NY) were used to
focus the microscope objective. Samples were diluted 10–2,000
times in filtered PBS to ensure that the number of particles in the
field of view was below 200 per image. Of each sample, 10 videos
of 30 s were captured with the camera shutter set at 33.31ms
and the camera gain set at 400. All samples were analyzed
with the instrument software (NTA 2.3.0.15) using a threshold
of 10, which was based on the exponential decay constant of
the summed intensity histogram of all frames in each movie
(MATLAB, v.7.9.0.529; Mathworks, Natick, MA).
Figure 2B shows the measured particle size distributions of
the EV samples. We estimate the smallest detectable EV for NTA
to be 70–90 nm (24).
TRANSMISSION ELECTRON
MICROSCOPY
Cancer-ID Specific Method and Operating
Principle
TEM has become the standard technique to confirm the presence
of EVs in samples (27). TEM transmits electrons through
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FIGURE 1 | Concentration, size, and density of plasma particles. 3D representation of concentration, size, and density of extracellular vesicles (dark green circle),
platelets (blue), and the high-density lipoproteins (HDLs, gray circle), low-density lipoproteins (LDL, gray triangle), very low-density lipoproteins (VLDLs, gray star), and
chylomicrons (CM, gray square) during fasting in blood. The average and standard deviation (lines) of the three parameters are indicated in the figure. Values are
derived from the literature (5, 7, 11). The frequency of the large tumor-derived extracellular vesicles (ltdEVs, light green circle) determined in the Cancer-ID program and
the small tdEVs (stdEVs, light green square) estimated using the frequency of ltdEVs (8–10).
sufficiently thin (<100–200 nm for biological materials) samples
to make images with possibly subnanometer resolution (28).
Particles from the sample are adhered to a carbon-coated formvar
grid. Because EVs compete with other negatively charged
particles for space on the grid, removal of soluble proteins and/or
salts, for example by size exclusion chromatography (SEC) (29)
and/or concentration, is required prior to incubation with EV
samples. In addition, because TEM is performed in vacuum,
EV samples are fixed with paraformaldehyde. After fixation and
adhesion, the grid is placed on a droplet of contrast agent (uranyl
acetate). A filter paper is used to remove the excess of contrast
agent, and the grid is dried at room temperature (30).
Next, the grid is placed in the vacuum chamber of a FEI
Tecnai 12 transmission electron microscope (FEI, Eindhoven,
Netherlands). The sample is exposed to an electron beam,
and images are constructed based on the detected transmitted
electrons (Figure 3A). The contrast agent scatters electrons
efficiently and stains the background more efficiently than the
EVs. Consequently, EVs appear as bright particles on top of a
dark background.
EV Definition
Water, the main cargo of an EV, is evaporated upon TEM
resulting in a deformation of EVs, which often appear as “cup-
shaped” (31–34) or “saucer/doughnut-shaped” particles (35–
37) (Figures 3C–F). Particles, not having water as their major
component, maintain their original structure during TEM. For
example, lipoproteins appear spherical, and protein aggregates
have an irregular shape. Therefore, we define EVs as cup-shaped
particles larger than 30 nm (13).
Value Added by Cancer-ID
We show that TEM images taken by operator selection, the
current standard within the EV field, can be used to demonstrate
the presence of EVs in a sample. However, the examination
of the morphology of EVs by TEM shows an operator bias in
their identification (13), which may lead to “cherry picking”
and emphasizes the importance of an automated and objective
assessment of EV identification. Two important steps to improve
the comparability and reproducibility of TEM for monitoring
the quality of EV samples are (1) to take images at predefined
locations and (2) provision of both close-up and wide-field
images, as adopted by MISEV2018 (38).
Relevance for Cancer Diagnostics
Although with appropriate sample preparation, TEM can image
EVs down to 30 nm, the contrast of TEM images is often
insufficient to distinguish EVs from similar sized non-EV
particles (Figure 3B). Moreover, to identify detection markers
on tdEVs, immuno-gold labeling (34) is necessary. However, the
main limitation of TEM for tdEV detection is the low throughput
because of the scarcity of tdEVs among other abundant particles
in plasma (see Table 1). Therefore, TEM can be used to evaluate
the quality and presence of EVs but is not a relevant technique
for identification of tdEVs in plasma samples.
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TABLE 1 | Overview of the techniques used in Cancer-ID.
Method References § Information obtained DL* (nm) Thr* (prt/h) T* (h)a
SURFACE
Single TEM (13) Transmission Electron Microscopy Morphology, size 30 9 × 103 2 × 107
SEM (15) Scanning Electron Microscopy Topography, size 50 50 4 × 102
AFM (15) Atomic Force Microscopy Morphology, bending
modulus
30 3 × 103 50
Raman (15) Integrated Photonics Lab-on-Chip
Devices for Raman Spectroscopy
Chemical composition 80 100 2 × 103
Electrochemistry (19) AFM-SEM-Raman Concentration, antigen
expression
– 2 × 107 0.5
Bulk SPRi (22) Electrochemistry Antigen expression – 30 × 107 3 × 10−2,b
SUSPENSION
Single NTA (23) Preparation of EV Samples Particle size distribution 30 400 9 × 108
Raman (18) Raman Microspectroscopy in
Suspension
Chemical composition 80 9 × 104 6 × 107
FCM (21) Surface Plasmon Resonance Imaging Antigen expression,
refractive index
200 6 × 106 4 × 106
FM (8) Flow Cytometry Antigen expression 1,000 4 × 106 2 × 1011
*DL, detection limit; Thr, throughput in total number of (generic) particles per hour; T, expected time needed to find 1 tdEV (specifically) in a typical plasma sample.
aThis column clarifies the need for in situ enrichment and sensitive detection for diagnostic applications. Nonenriched techniques are expected to process a third of all particles in 1 µl
individually or spread out over a flat surface before encountering 1 tdEV. Considering that the total area of all particles (lipoproteins and EVs, see Figure 1) distributed over a densely
packed monolayer is ∼36 cm2, the following assumptions were made:.
TEM: 2.2 × 2.2 µm2 imaging area, imaged in 1min, with a capturing efficiency of 21%. SEM: 25 µl sample, 50µm × 7mm capturing area, 10% capturing efficiency, 10% detected
fraction (due to sensitivity limitations), 5min per 10 × 10 µm2 image. AFM: 25 µl sample, 50µm × 7mm capturing area, 10% capturing efficiency, 45min per 25 × 25 µm2 image.
Raman on surface: 25 µl sample, 50µm × 7mm capturing area, 10% capturing efficiency, 1% detected fraction (due to sensitivity limitations), 17min per 30 × 30 µm2 image.
Electrochemistry: Processing any sample takes ∼30min regardless of the number of tdEVs. bSPRi: Processing time is 2min. NTA: This technique can process 100 particles in 15min,
i.e., 1010 measurements have to be performed to find all tdEVs in 1 µl of plasma. Raman in suspension: ∼ 1012 measurements of 38ms; 50% of particles fall below the detection limit.
Flow cytometry: The sample must be diluted 109 times to ensure that one detection event corresponds to one particle; 3 µl can be processed in 1min; 50% of particles fall below the
detection limit. Fluorescence microscopy: An area of 100 × 100 µm2 can be imaged in 0.2 s with an automated stage; 99% of particles fall below the detection limit.
Please note that 200 µl of sample is needed before the 104 EVs/µl limit of detection is reached.
SCANNING ELECTRON MICROSCOPY
Cancer-ID Specific Method and Operating
Principle
EV samples are fixed in paraformaldehyde, followed by
gradual dehydration from 70 to 100% ethanol in water
with a 10% concentration increment step every 5–10min.
Subsequently, chemical drying of the sample can be achieved
using 1:1 hexamethyldisilazane (HMDS) in ethanol for 3–
5min, followed by 100% HMDS for 3–5min more. EVs are
dehydrated and dried to maintain their morphological and
surface features with minimal deformation in the vacuum
chamber of the SEM (39, 40). EV samples are coated with
gold to increase the image contrast and avoid surface charging.
Furthermore, the sample must be placed on a conductive
substrate during imaging. The entire procedure is conducted at
room temperature.
In SEM imaging, a focused beam of electrons scans
the surface of a sample interacting with all atoms in the
sample (Figures 4A, B). Detection of the secondary electrons,
originating from the outer layers of the sample, enables
to visualize the topography of a sample. The amount of
backscattered electrons, originating from the deeper layers of the
sample, is associated with the atomic number of the atoms in
the sample.
EV Definition
Since the LNCaP EV sample is derived from cell culture, we do
not expect particles like lipoproteins to be present in this sample.
Figure 4B shows round particles (white arrows) in lower and
higher magnification, which we define as EVs.
Value Added by Cancer-ID
We show that cells and EVs captured on functionalized substrates
and in solution can be imaged by SEM.
Relevance for Cancer Diagnostics
SEM can be used to visualize the topography of tdEVs, as small as
50 nm, but is unable to discriminate EVs from non-EV particles
with a similar morphology. In order to confirm the nature of
the particles, immunogold labeling or correlative techniques are
required such as AFM, Raman, or fluorescence imaging. Cryo-
TEM and cryo-SEM have been suggested superior techniques in
retaining the EV morphology when compared to TEM and SEM
because of the effect of fixation and air dehydration in the vacuum
chamber (34); however, our results (Figure 4) support that
gradual dehydration of EV samples in ethanol series prior to SEM
imaging allows the maintenance of EV morphology. The main
limitation of SEM similarly to TEM is the low throughput, as a
large area needs to be processed before tdEVs are encountered
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FIGURE 2 | Particle size distributions of extracellular vesicle (EV) samples measured using nanoparticle tracking analysis (NTA). (A) Schematic representation of the
NTA setup. A laser beam illuminates the particles in suspension. The light scattered by particles undergoing random motion (white arrow) is collected by a microscope
objective and detected by an multiplying charge-coupled device (EMCCD) camera. The random motion of the particles under Brownian motion can be related to their
size. (B) NTA analysis results of the PC3EV (blue), LNCaP EV (green), red blood cell EV (red), and the platelet (black) EV samples, respectively. The bin width is 10 nm.
The mean particle size and concentration in the PC3EV sample are 172 ± 4 nm and 1E8 particles/ml, respectively. The mean particle size and concentration in the
LnCaP EV sample are 167 ± 4 nm and 1E8 particles/ml, respectively. The mean particle size and concentration in the red blood cell EV sample are 148 ± 4 nm and
1E8 particles/ml, respectively. The mean particle size and concentration in the platelet EV sample are 89 ± 5 nm and 4E7 particles/ml, respectively. Because the
uncertainty in the determined concentration with NTA is unknown, the determined concentration should be interpreted as an order of magnitude estimate (24). Images
adapted from Lee et al. (25) and van der Pol et al. (26).
(see Table 1). Therefore, SEM is not a relevant technique for the
detection of tdEVs in plasma samples.
ATOMIC FORCE MICROSCOPY
Cancer-ID Specific Method and Operating
Principle
EVs are added onto a poly-L-lysine-coated coverslip (41–44).
Next, the sample chamber is filled with filtered PBS (0.2µmfilter;
VWR International, Radnor, PA) and placed on the AFM. During
AFM imaging, a cantilever with a nanometer-sized tip probes the
sample surface (Figure 5A) (45). Deflection of the cantilever is
measured with a laser and photodiode. AFM images are acquired
in PeakForce Tapping mode on a Bruker Bioscope catalyst setup
using minimal imaging force providing information about the
topography of the samples surface. Mechanical properties can be
obtained by applying a defined force perpendicular to the surface
(indentation), providing force–indentation curves, as presented
in Figure 5B.
EV Definition
With AFM, we characterize an EV as a particle of at least
25 nm in height with a spherical shape. Aggregates typically
have a nonspherical shape and therefore can be excluded. The
nanoindentation response is used to identify single EVs (42, 44).
A typical indentation curve is characterized by a (close-to) linear
initial increase in force followed by a softening and finally bilayer
pinching close to the substrate (Figure 5B, red curve).
Value Added by Cancer-ID
Unique characteristics, like deformability, of tdEVs compared
to EVs of other origin still need to be explored. Examples
of AFM measurements of LNCaP EVs and platelet EVs are
shown in Figures 5C,D. Importantly, it should be noted
that AFM imaging per se is not distinguishing between
EVs and lipoproteins. Therefore, a good purification
protocol is necessary (combining gradient- and size-
based isolation methods) in order to assure only EVs
are present.
Relevance for Cancer Diagnostics
Because of the nanometer position sensitivity and subpiconewton
force sensitivity, AFM can be used to determine the topography,
morphology, and mechanical characteristics of single EVs,
and differences between EVs of different origins can be
investigated (42, 44). AFM is a low-throughput technique since
only several particles can be observed at a time. For the
moment AFM has not been shown to be a suitable technique
for tdEV identification and enumeration in plasma samples
(see Table 1).
RAMAN MICROSPECTROSCOPY IN
SUSPENSION
Cancer-ID Specific Method and Operating
Principle
EV samples are diluted in PBS to a concentration of ∼109
particles/ml (as measured by NTA) and placed on a well
glass slide, covered with a glass cover slip, and sealed with
glue. Next, the glass slide is placed under the microscope
objective (Figure 6A). A Raman optical tweezers [home-built
system as described in Enciso-Martinez et al. (18)] is used
to (i) trap single particles diffusing near the high intensity
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FIGURE 3 | Transmission electron microscopy (TEM) of extracellular vesicle (EV) samples. (A) Schematic representation of TEM imaging for EV samples. The sample
on a grid is exposed to an electron beam, and images are constructed based on the detected transmitted electrons. The uranyl acetate (UA) scatters electrons
efficiently, which results in negative contrast. EVs and lipoproteins (LPs) have a low electron density and are seen as bright particles in a dark background (13). (B) TEM
images of the EV samples from PC3 and LNCaP and of red blood cells and platelets after size exclusion chromatography. The scale bar corresponds to 500 nm (25).
part of the focus (Figure 6A) and (ii) detect both Rayleigh
and Raman scattered photons synchronously. The trapping
of a single particle is detected by Rayleigh scattering, and
the corresponding Raman spectrum discloses the chemical
composition (18, 46).
EV Definition
The Raman spectra of submicrometer particles in biofluids have
distinct spectral features depending on the nature of the particle
or the source of EVs.
Value Added by Cancer-ID
The procedure to trap, release, and acquire sequentially the
spectrum of single EVs in the focal volume is automated (18).
Furthermore, EVs can be distinguished from lipoproteins and
EVs from different sources, like PC3 EVs, LNCaP EVs, and
red blood cell EVs. EVs show distinctive peaks at 1,004 and
1,607 cm−1 (phenylalanine) and a larger protein contribution
at 2,811–3,023 cm−1 than lipoproteins (Figures 6B,C) (25, 46).
The Raman spectrum of red blood cell EVs is different from
PC3 EVs and LNCaP EVs around 1,200–1,385 cm−1 and
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FIGURE 4 | Scanning electron microscopy (SEM) of extracellular vesicle (EV) samples. (A) Schematic representation of a SEM setup. SED, secondary electron
detector; BED, backscatter electron detector. (B) The sample is illuminated by the electron beam. Electrons interact with the sample at different depths, resulting in
emitted electrons from the surface (secondary electrons) and from deeper layers (backscattered electrons). (C) SEM image of LNCaP EVs indicated by arrows. The
large object in the left lower corner is part of a LNCaP cell floating in the cell supernatant and was imaged to show that the contrast of EVs is similar to cells. The scale
bar represents 2µm. (D) Higher magnification allows imaging of smaller particles, possibly EVs, with lower contrast. The scale bar represents 500 nm.
1,510–1,631 cm−1 (46). Further classification of EVs and
lipoproteins was achieved by multivariate analysis and
convolutional neural networks analysis (25, 47).
Relevance for Cancer Diagnostics
Differences in chemical composition are shown between EVs
and lipoproteins, and tdEVs compared to red blood cell EVs.
However, a limitation of Raman is the throughput. As an
example, a typical acquisition time per EV is 1 s (18). Hence, it
has become clear that enrichment of tdEVs is needed prior to
Raman analysis. Nevertheless, spontaneous Raman spectroscopy
provides information on the chemical composition of single or
multiple EVs in solution or on a surface in a noninvasive and
label-free manner (18, 25, 46, 48–52).
INTEGRATED PHOTONICS LAB-ON-CHIP
DEVICES FOR RAMAN SPECTROSCOPY
Cancer-ID Specific Method and Operating
Principle
Two types of lab-on-chip devices were developed by Cancer-
ID and fabricated in the cleanroom of the MESA+ Institute
of Technology. From a technological perspective, Cancer-ID
exploits the possibility of lab-on-a-chip devices to localize
light in ways that are impossible with traditional optics. For
example, compared to optical trapping using a microscope
objective (Raman Microspectroscopy in Suspension), we expect
that combining multiple beams will result in higher field
gradients and therefore trapping of smaller single EVs. To proof
the principle, device type 1 contains multiple waveguides, each of
which emits a narrow beam of light towards the center of a fluidic
microbath, as shown in Figure 7A. The resulting multiple beams
combine coherently to form an interference pattern withmultiple
spots of high light intensity, each serving as an optical trap
sufficiently strong to trap single submicrometer particles near the
microbath center. The same concentrated light induces a Raman
spectrum from the trapped particle for label-free identification.
To increase the throughput, the well may be replaced by a flow
cell in future versions.
To increase throughput compared to optical trapping using
a microscope objective (section Raman Microspectroscopy in
Suspension), device type 2 combines an enrichment step with the
simultaneous detection of Rayleigh and Raman scattered light
from multiple EVs. EVs in suspension bind to antibodies at the
surface of a spiral waveguide, which is placed at the bottom of
a microfluidic channel as shown in Figure 7B (54). A laser field
propagates inside the waveguide and produces an evanescent
field that probes the attached EVs simultaneously. The EVs will
scatter some of this light with characteristic Raman shifts. A
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FIGURE 5 | Atomic force microscopy (AFM) of extracellular vesicle (EV) samples. (A) Schematic representation of the AFM setup. In AFM, a cantilever interacts with
the sample, and the reflected laser beam is detected by a photodiode (45). The experiments are performed in liquid (not depicted). (B) Example of force–indentation
curves (distance z) of the extend and retract response on an EV (45). AFM images of responses of (C) LNCaP EVs and (D) platelet EVs to an applied force before (first
row) and after indentation (second row). Both the LNCaP and the platelet EVs can change shape upon indentation. The different responses are illustrated by the
cross-sections (bottom row), taken at the indicated spots in the corresponding AFM images above (red, before indentation; black, after indentation). Scale bars
represent 50 nm.
significant portion of this light re-enters the waveguide and can
be collected from the entrance through the same objective that
launched the excitation light.
EV Definition
An EV is identified based on the acquired Raman spectrum
of the trapped particle. The obtained spectra may be cross-
referenced with EV spectra already acquired with standard
spontaneous Raman tweezers (Raman Microspectroscopy in
Suspension). Furthermore, using device type 2, EVs are bound to
the surface of a spiral waveguide by a specific antibody.
Value Added by Cancer-ID
Both device types are still under development. So the throughput
and detection limit remain to be determined. In device type 1,
integration of the multiple beam trap with a microfluidic channel
opens new possibilities of controlled particle delivery to the trap
and particle sorting with pressure-driven flow, which may allow
the detection of smaller EVs. In device type 2, specific capture of
tdEVs from the plasma is possible by the use of antibodies coated
on the surface of a spiral waveguide using the chemistry used in
AFM-SEM-Raman and Electrochemistry.
Relevance for Cancer Diagnostics
Based on the differences in chemical composition, tdEVs
can be distinguished from non-EV particles like lipoproteins
and EVs from other origin. Furthermore, enrichment can
be achieved by the use of antibodies bound to the surface
of a waveguide. Raman spectroscopy of EVs provides
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FIGURE 6 | Raman spectroscopy of extracellular vesicle (EV) samples. (A) Particles in suspension are loaded in a well glass slide that is mounted under a microscope
objective. Incident light illuminates the sample, and both Raman and Rayleigh light are backscattered, collected by the lens, and detected by a spectrograph. Raman
spectra corresponding to (B) single and (C) multiple PC3 EVs (blue), LNCaP EVs (green), red blood cell EVs (red), and lipoproteins in plasma (black). (A) is adapted
from Enciso-Martinez et al. (18).
FIGURE 7 | Integrated photonics based lab-on-a-chip Raman spectroscopy. (A) Device type 1: Camera image of a device with 16 waveguides for trapping and four
waveguides for detection. The device is actuated with light from an input fiber that is embedded in a fiber array unit (FAU) at the lower right-hand side. The various
structures light up as a result of light scattering, causing some saturation of the camera. The solid red lines indicate the chip edges. 1, FAU; 2, excitation-waveguide
circuitry; 3, microfluidic bath with the central trapping region; 4, detection-waveguide circuitry; 5, light from the trap that is coupled out by the detection waveguides.
Here, the detection waveguides collect light as a result of direct illumination and scattering (from Loozen et al. (53)). (B) Device type 2: Spiral waveguide with the
Raman pump light traveling inside the waveguide. The Raman signal is (partially) scattered back into the waveguide and collected at the front entrance. Reproduced
with permission from Lee (54).
information on the chemical composition of single or
multiple EVs in a noninvasive and label-free manner and
may be simplified using integrated photonics lab-on-a-chip
devices. The analysis time per particle remains to be measured
before estimating the tdEV throughput and potential of the
specific technique.
AFM–SEM–RAMAN
Cancer-ID Specific Method and Operating
Principle
The surface of stainless-steel substrates is modified with a
carboxydecyl phosphonic acid monolayer to covalently link
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FIGURE 8 | Atomic force microscopy (AFM), scanning electron microscopy (SEM), and Raman spectroscopy of extracellular vesicle (EV) sample. Schematic
representation of the system: antibody-functionalized stainless-steel substrate examined with SEM, AFM, and Raman for correlated multimodal analysis of individual
EVs. Image adapted from Beekman et al. (15).
anti-EpCAM antibodies to the substrate (Figure 8) (55). EVs
are incubated in poly(dimethylsiloxane) (PDMS) microchannels.
The microchannels are washed to remove nonspecifically bound
material. Next, EVs are incubated with paraformaldehyde in PBS
for 15min. The PDMS is removed by immersion in deionized
water, 70% ethanol in water, and finally 100% ethanol for 5min
each step. Dehydration of tdEVs was followed by overnight
drying. Alignment markers are embedded on the stainless-
steel substrate by injecting patterned microfluidic channels with
cyanoacrylate glue. The microscale alignment markers facilitate
retracing individual EVs in the sample stages of the AFM (MFP-
3D, Asylum Research, Wiesbaden, Germany), SEM (JEOL JSM-
6610LA Analytical SEM, JEOL, Nieuw-Vennep, Netherlands),
and Raman microspectroscopy ]home-built system as described
in Beekman et al. (15)]. SEM is used here to select regions of
interest and confirm that the surface is successfully functionalized
based on the attachment of EVs (15).
EV Definition
EVs are identified by SEM and a Raman spectrum with lipid-
protein peaks (2,811–3,023 cm−1) characteristic for EVs. The
functionalization of the substrate ensures that the EVs are
of epithelial cell origin permitting the determination of the
mechanical characteristics, like deformability, of the tdEVs
by AFM.
Value Added by Cancer-ID
The use of only one technique is often insufficient to identify
and characterize EVs, as discussed in the previous sections
(38). For example, both EVs and lipoproteins appear to be
spherical by SEM. By combining SEM with AFM and Raman,
we measure characteristics like size, chemical composition,
and deformability to add certainty to the identification of
tdEVs (15).
Relevance for Cancer Diagnostics
Using a combination of AFM, SEM, and Raman and the capture
of tdEVs to a functionalized surface helps to distinguish EVs
from non-EV particles and adds certainty to the origin of
the EV.
In principle, this platform does not require distinguishing
tdEVs from other species since enrichment is done by the
functionalized surface (as assumed in Table 1). Since SEM
measurements are faster than AFM or Raman, SEM was used
for initial confirmation of tdEV presence on a chip; after
enrichment, 1,000 tdEVs (of >100 nm) can be imaged in 1 h.
Since AFM detects the more abundant much smaller particles
(>30 nm) as compared to SEM (>100 nm), the fact that AFM
is slower in terms of imaged square micrometer per unit time,
is offset by a greater number of observed tdEV per imaged
square micrometer, such that 1,000 tdEVs can be imaged in
2 h. For Raman, detection of 1,000 tdEVs would require about
100 measurements of 17min each followed by several days of
data processing.
ELECTROCHEMISTRY
Cancer-ID Specific Method and Operating
Principle
Interdigitated nanoelectrodes (nIDEs), fabricated in the
cleanroom of MESA+ Institute for Nanotechnology, are
surface-modified with poly(ethylene glycol) diglycidyl ether
to form an amine-reactive antifouling layer (Figure 9A) (56).
Antibodies against EpCAM (VU1D9 clone) are covalently
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FIGURE 9 | Electrochemical detection of extracellular vesicle (EV) samples. (A) Scheme showing selective capture and in-situ labeling of EVs followed by enzymatic
amplification of redox species and redox cycling. (B) Cyclic voltammograms recorded for a very wide range of EV concentrations. (C) Recorded current at 0.4 V for
varying concentrations showing linear response over six orders of magnitude. Image adapted from Mathew et al. (19).
linked to this layer and the remainder of the surface blocked
with bovine serum albumin (BSA). EV samples are introduced
onto the device to allow binding to the electrodes. After
incubation, a biotinylated reporter anti-EpCAM is introduced.
The biotin moiety conjugates to streptavidin coupled to
alkaline phosphatase (ALP). ALP, only present on EpCAM-
positive particles, converts an electrochemically inert molecule
(para-aminophenyl phosphate) into a redox-active species
(para-aminophenol), to yield a first amplification phase. Next,
the para-aminophenol undergoes redox cycling, providing a
second amplification phase.
EV Definition
An increase in the redox current upon binding of particles to the
nIDEs defines the presence of EVs. EVs from different species
can be distinguished from each other by employing targeted
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antibodies, yielding a very high selectivity. For example, the
signal from platelet EVs did not vary from the background signal,
whereas the introduction of LNCaP EVs markedly increased the
signal (Figure 9B) (19).
Value Added by Cancer-ID
This new and sensitive technique was developed by
Cancer-ID in collaboration with researchers from the
NanoElectronics group at University of Twente, Netherlands.
Several examples of sensitive integrated systems for (td)EV
detection exist (57–60) (Lorencova). A unique feature of
the technique discussed here is the ability to detect a low
concentration of EVs with a low antigen expression. The
linear response covers a broad range of concentrations,
which largely overlaps with concentrations of tdEVs in
patient blood.
Relevance for Cancer Diagnostics
Using electrochemistry, tdEVs can be discriminated from non-
EV particles and EVs from other origin based on the expression
of EpCAM. A dilution series of LNCaP EVs in PBS showed a
linear response ranging from 5 × 103-109 tdEVs/ml (Figure 9C)
(19), which overlaps with the expected tdEV concentration in
plasma (10), showing that this technique is promising to identify,
count, and characterize tdEVs in the range of clinical samples.
Evaluation of the technique with plasma patient samples and
association of the readout with clinical outcome remain to
be tested.
The functionalized device is incubated with tdEV-containing
sample and subsequently with reporter antibodies and redox
mediator. In the experiments performed in the paper, these
incubations were done over excessively long periods (2.5 h
in total) to maximize the efficiency but, once optimized,
can probably be performed several minutes to 1 h. The
FIGURE 10 | Surface plasmon resonance imaging (SPRi) analysis of extracellular vesicles (EVs). (A) Schematic of a SPRi setup. A SPRi signal is generated when the
sensor surface is illuminated at various angles with light and surface plasmons are excited (61). The resonance angle, specific angle (beam 2) where maximum
plasmon excitation and minimal internal reflection occurs (62), depends on the refractive index contrast near the interface in the evanescent field. (B) The 48 spots on
the SPRi sensor surface can be coated with different antibodies. In this example, only nine antibody-coated spots on the SPRi sensor surface are shown. (C) An EV
sample is exposed to the SPRi sensor and measured for 60min. The attachment of an ensemble of EVs to a specific antibody spot causes a change in the refractive
index and generates a SPRi signal over time (16). (D) The SPRi signals after incubation with four prostate-cancer-derived EV samples are shown. The two CD63
clones show the same results for all samples. All samples are slightly positive for CD63, EGFR, and CD9. A higher positivity is seen for EpCAM and lactadherin. The
SPRi signals for the 22RV1-EV sample are higher compared to the other samples (16).
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cyclic voltammetry measurements were performed in 20min,
regardless of the concentration of tdEVs (5 × 103-109/ml of
sample). Using patient plasma samples rather than cell culture
medium may increase the background signal, thereby reducing
the sensitivity of the technique. Nevertheless, compared to other
techniques, electrochemical methods hold great promise to be
applied in a clinical setting because of the high throughput.
SURFACE PLASMON RESONANCE
IMAGING
Cancer-ID Specific Method and Operating
Principle
The surface of a SPRi sensor is coated with a conductive gold
layer and a 3D hydrogel-like layer to reduce nonspecific binding
of non-EV particles to the surface (Figure 10A). Antibodies
are printed on 48 spots on the sensor (Figure 10B), including
isotype controls and a control (PBS) to correct for dissociation
and nonspecific binding (16). Next, the surface is washed and
deactivated by incubation with 2-amino ethanol followed by
BSA. After an EV sample is exposed to the sensor, EVs bind to
the antibody-coated sensor spot, which increases the refractive
index near the sensor surface. This increase in refractive index is
measured in time using the angle scanning principle of the IBIS
MX96 instrument (IBIS Technologies, Enschede, Netherlands)
and corresponds to the number of particles captured on the spot
(Figure 10C).
EV Definition
With SPRi, EVs are identified based on their antigen exposure.
EVs bind to antibodies printed on the sensor, e.g., anti-CD9, anti-
CD63, antiepidermal growth factor receptor (anti-EGFR), anti-
EpCAM, antiolfactory receptor 51E2 (anti-OR51E2), transient
receptor potential cation channel subfamily M member 8
FIGURE 11 | Flow cytometry of extracellular vesicle (EV) samples. (A) In flow cytometry, a single particle suspension is hydrodynamically focused with sheath fluid
(arrows) to intersect a laser. Light coming from the particle is collected by a forward scatter detector (FSC), a side scatter detector (SSC), and multiple fluorescence
detectors (FL1, FL2, etc.). (B) Fluorescence (green dashed line) is isotropic and can be used to determine antigen expression and cellular origin. Scatter (blue solid
line) has an angular distribution that depends on the size and refractive index of the particle (here, 200 nm polystyrene). Knowledge of the flow cytometer collection
angles and Mie theory allows derivation of particle size and refractive index from the measured scatter signals (14, 20). (C) Scatter plots of side scatter vs.
fluorescence for the PC3EV sample stained with CD63-PE (left), the LNCaP EV sample stained with EpCAM-Alexa Fluor 647 (center), and the platelet EV sample
stained with CD61-FITC (right). In PC3EV sample, 14.1% was found to be positive for the EV marker CD63; in the LNCaP EV sample, 7.8% was found to be positive
for cell surface epithelial marker EpCAM; and in the platelet EV sample, 5.4% of the particles was found to be positive for CD61. BB, blocker bar; FL, fluorescence.
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FIGURE 12 | Epithelial cell adhesion molecule (EpCAM) immunomagnetic enrichment and fluorescence microscopic (FM) detection of extracellular vesicle (EV)
samples. (A) Principle of the CellSearch system. ACCEPT analysis of two CellSearch cartridges corresponding to EpCAM-enriched blood sample of a healthy donor
(Continued)
Frontiers in Oncology | www.frontiersin.org 14 June 2020 | Volume 10 | Article 608
Rikkert et al. Tumor Derived EVs
FIGURE 12 | (B) without and (C) with LNCaP EVs spiked. CD45 is depicted in red, CK in green, and 4′,6-diamidino-2-phenylindole (DAPI) in blue. The objects falling
in the applied tdEV gate are depicted as blue dots in the scatter plots of CD45 mean intensity vs. CK mean intensity. The other particles are shown as gray dots.
Thumbnail examples of four objects are shown. The CD45+ and CK+ particles are attached to the leukocytes, as illustrated. Scale bars indicate 6.4µm. (D,E) show
Kaplan Meier plots of overall survival of 956 metastatic colorectal, prostate, breast, and nonsmall cell lung cancer patients. Patients were grouped based on their (D)
circulating tumor cells (CTC) or (E) tumor-derived EV (tdEV) counts demonstrating the equivalent prognostic power of CTCs and tdEVs (9).
(TRPM8), and lactadherin, see Figure 10D. SPRi detects a
difference in response on the antibody spots between EV samples
derived from different cell lines.
Value Added by Cancer-ID
Characterization of EVs by SPRi, using the IBIS MX96, revealed
the ability to detect cell surface antigens present at relatively low
antigen densities compared to cells, as their presence could not
be detected by flow cytometry (16).
Relevance for Cancer Diagnostics
SPRi can be used to distinguish tdEVs from non-EV particles and
EVs derived from other cells based on the antigen expression.
The IBIS MX96 is able to detect antigens present at a low density
on EVs compared to cells (16). SPRi has superior sensitivity
when compared to flow cytometry (16) and ELISA (63). However,
the required EV concentration to perform the herein reported
measurements is high (2 × 108 EVs/mL), and not within the
range of the expected tdEV frequency in plasma patient samples.
A different configuration (nano-plasmonic exosome (nPLEX)
assay) has been suggested by Im et al. to increase the throughput
and make feasible the detection of tdEVs in ascites of ovarian
cancer patient samples (63).
FLOW CYTOMETRY
Cancer-ID Specific Method and Operating
Principle
EV samples are diluted in PBS (21-031-CV; Corning, Corning,
NY) to prevent swarm detection (64) and stained with
fluorescently labeled antibodies. Antibody aggregates are
removed by centrifugation prior to use. The “antibody
supernatant” is added to the EV sample followed by a 2-h
incubation step, which is stopped by diluting the incubated
sample with PBS.
In a flow cytometer, the sample is hydrodynamically focused
with sheath fluid to intersect a laser beam (Figure 11A). Scattered
light and fluorescence from the particle are collected by a
forward scatter detector, a side scatter detector, and multiple
fluorescence detectors (65) (Figure 11B). The measured scatter
and fluorescent signals per particle can be represented and
analyzed using scatter plots as shown in Figure 11C. In the
works referenced here, samples were analyzed on an A60-Micro
(Apogee, Hertfordshire, UK).
EV Definition
EV identification by FCM is commonly based on the expression
of one or more antigens, which are detected using fluorescent
immunostaining. Recently, we found that the refractive index of
particles can be used as an additional parameter to distinguish
EVs from lipoproteins (21). We therefore define an EV as a
particle that expresses detectable levels of one or more antigens
and has a refractive index<1.42.
Value Added by Cancer-ID
Within Cancer-ID, a technology to determine the size and
refractive index of submicrometer particles was partly developed,
evaluated, and used to find new applications. Based on refractive
index, for example, EVs can be differentiated from lipoproteins
without antibody labeling (21). Refractive index determination
was used to show that generic EV dyes, which are commonly
used to label EVs in FCM measurements, do not label all EVs
and do label non-EV particles (17). The combination of antibody
labeling and refractive index determination could be used to
increase specificity of EV detection. Furthermore, the side scatter
sensitivity of a conventional flow cytometer was improved 30-
fold by systematically modifying the hardware, and a method was
developed to quantify the scatter sensitivity of a flow cytometer.
Relevance for Cancer Diagnostics
FCM measures light scattering and fluorescence from thousands
of individual particles per second. Although detection of the
smallest single EVs is possible (66), only the most sensitive
commercial flow cytometers are able to detect EVs with a
diameter <200 nm (67). Based on the combination of an
antibody and the refractive index, it is possible to discriminate
tdEVs from lipoproteins and EVs from other origin. However,
plasma samples are typically prediluted 10–100 times before
measurements to prevent swarm detection (as assumed in
Table 1). This dilution means that the detection of the few tdEVs
that might be present in the plasma sample is impossible.
However, FCM provides information on the concentration,
cellular origin and biochemical composition, size, and refractive
index of single EVs (14, 20, 68).
IMMUNOMAGNETIC EPCAM
ENRICHMENT FOLLOWED BY
FLUORESCENCE MICROSCOPIC
DETECTION
Cancer-ID Specific Method and Operating
Principle
Blood of individuals is collected in CellSave blood collection
tubes (Menarini, Huntingdon Valley, PA). After centrifugation
of 7.5mL of the blood for 10min at 800 g, the sample is placed
in the CellTracks Autoprep (Menarini, Huntingdon Valley, PA).
The Autoprep aspirates and discards the plasma, whereas the
blood cell fraction is incubated with anti-EpCAM (VU1D9 clone)
ferrofluid (Figure 12A, step 1). The particles (cells and EVs)
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bound to the ferrofluid are separated from the rest of the
blood by the application of magnetic forces (step 2). Following
the immunomagnetic isolation, EpCAM-enriched particles are
stained with the nuclear dye 4′,6-diamidino-2-phenylindole
(DAPI) and fluorophore-conjugated antibodies recognizing the
epithelial specific cytokeratins 8, 18, and 19 (CK-PE) and the
leukocyte-specific marker CD45 (CD45-APC) (step 3). The
stained sample is loaded in a cartridge and placed between two
magnets configured in such a way that all stained EpCAM+-
enriched particles homogeneously align on the glass slide on
the surface of the cartridge (step 4). The cartridge is scanned
using the CellTracks Analyzer II (Menarini, Huntingdon Valley,
PA), a fluorescence microscope equipped with a 10× 0.45 NA
objective (step 4). The images are analyzed using the open-source
ACCEPT software to identify circulating tumor cells (CTCs),
tdEVs, leukocytes, and leukocyte derived EVs (69) (step 5).
EV Definition
tdEVs are defined as EpCAM+, CK+, DAPI–, and CD45–
particles. A gate for their automated enumeration from the
CellSearch image data sets has previously been reported (8).
Value Added by Cancer-ID
In the frames of the Cancer-ID program, we reanalyzed digitally
stored FM image data sets of retrospective clinical studies
acquired after EpCAM enrichment. Our results suggest that large
tdEVs (>1µm), coisolated with CTCs, are negatively associated
with the overall survival of metastatic prostate, colorectal,
breast, and nonsmall cell lung cancer patients in a similar way
as CTCs (Figure 12) (9) and could contribute in monitoring
the disease and assessing therapeutic efficacy. However, the
existing technique was developed for the detection of CTCs and
eliminates the detection of smaller tdEVs or tdEVs with low
antigen density even if they have been isolated by the anti-
EpCAM ferrofluid.
To evaluate whether tdEVs from a model cancer cell line
can be isolated using the CellSearch assay, two samples were
used as a positive and negative control of the technique. Two
blood samples of 7.5ml, collected in CellSave tubes and drawn
from an anonymous healthy individual, were provided by the
TNW-ECTM-donor services (University of Twente, Enschede,
Netherlands). Both samples were processed with the CellSearch
system; however, the one sample remained intact without the
addition of any EVs (negative control), whereas the other one was
spiked with EVs produced from the EpCAM+ LNCaP prostate
cancer cell line (positive control). The application of a tdEV gate
resulted in 0 events in the negative control and in 3,772 events in
the positive control (Figures 12B,C).
This study was carried out in accordance with the
recommendations of Dutch regulations. The protocol was
approved by the Medical Ethical Assessment Committee Twente
(METC Twente). The subject gave written informed consent in
accordance with the Declaration of Helsinki.
Relevance for Cancer Diagnostics
The CellSearch system can be used to enrich CTCs and tdEVs
based on their EpCAM expression, as EpCAM is not expected to
be present on cells and EVs in blood of healthy individuals (70,
71). However, tdEVs isolated by the CellSearch system are limited
to the larger EVs (>1µm), as the technique was designed to
isolate CTCs; therefore, the plasma (obtained after centrifugation
at 800 g) containing the majority of EVs is discarded by
default. As a consequence, more than 95% of the total tdEV
population holding relevant clinical information is discarded.
Nonetheless, the subset of isolated large EpCAM+, CK+ tdEVs
from blood of cancer patients has a similar prognostic power
to CTCs in metastatic prostate, breast, colorectal, and nonsmall
cell lung cancer patients (Figure 12) and can complement CTCs
in the CellSearch assay. Processing the plasma samples with the
CellSearch assay and imaging of the enriched sample using a
fluorescence microscope with a higher NA objective is expected
to lead to increased tdEV detection with a higher offset when
compared to the tdEV counts detected in the respective processed
plasma samples of healthy individuals.
CANCER-ID INSIGHTS
Cancer-ID delivered new techniques and new insights to
explore tdEV detection. Taken the complexity of blood into
consideration, the necessity of enriching biological samples for
tdEVs becomes obvious. EVs secreted from prostate cancer
cell lines and EVs derived from red blood cells and platelets,
resembling the expected background of EVs in plasma, were
used to explore the utility of different techniques. The size
distribution of EV samples was characterized by NTA; the
EV size and/or morphology by TEM, SEM, and AFM; their
biochemical composition by Raman spectroscopy; and their
antigen expression profile by SPRi, FM, and FCM. The
techniques were able to detect or image EVs present in culture
supernatants from tumor cells. However, discrimination between
EVs and non-EV particles becomes difficult in complex samples
like plasma because non-EV particles outnumber EVs (Figure 1).
Furthermore, most techniques cannot identify the cellular origin
of single EVs and relate the measured signal or count to the
concentration of tdEVs in plasma. The results of all individual
techniques pointed out that a combination of more than one
parameters or techniques will increase the certainty that tdEVs
are being investigated, and immune affinity enrichment or
detection is needed to cover the large size and density range
of EVs.
EV isolation protocols have not been standardized within
the EV field (72, 73). Size-based isolation techniques, such
as size exclusion chromatography, can purify samples from
contaminating lipoproteins and soluble protein of a size
below 70 nm (29). Furthermore, centrifugation is often used
to isolate biomarkers from whole blood. In the Cancer-ID
program, we developed a model to predict the behavior of
particles (cells and EVs) in solution during centrifugation
and showed the coisolation of, for example, platelets and
large EVs after centrifugation (73). Moreover, although the
application of rate zonal centrifugation improved the separation
of platelets from EVs, the aforementioned isolation techniques
result in purification of EVs rather than enrichment of
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tdEVs. Similarly, other techniques such as the asymmetric-
flow field-flow fractionation can accurately separate exosomes
and exomeres based on their size (74); however, for the
characterization of EVs of interest, an additional pre-enrichment
step will be required.
By the use of affinity-based techniques using antibodies
directed to antigens expressed on tumor cells but not on
blood cells, we demonstrated the enrichment of large (>1µm)
EpCAM+ tdEVs from blood from metastatic cancer patients
(8, 9). EVs from different origin were eliminated in the enriched
sample. Efforts for the immunomagnetic enrichment of smaller
(<1µm) tdEVs from plasma samples based on EpCAM are
ongoing. The frequency of small tdEV shown in Figure 1 is
based on an extrapolation from the frequency of the large tdEVs,
and this surely will need to be validated. Moreover, whether
the small tdEV have a similar relation with clinical outcome
will need to be established. tdEV likely encompass different
subclasses; for example, those responsible for communication
with the environment and those involved in the process of
apoptosis of cancer cells and as such relation with clinical
outcome or its cargo being informative on the optimal treatment
will likely be different between these subclasses. Here, only the
EpCAM antigen was used to capture tdEVs; the use of different
or a mixture of antibodies recognizing different cancer-specific
antigens, such as VAR2CSA (75) and HsP70 (76, 77) could
increase the capture efficacy andmay identify different subclasses
of tdEVs. Identification of tdEV among the EpCAM-enriched
particles was obtained through identification of the presence of
intracellular cytokeratins; the use of different components of the
tdEV cargo might be important. Exploration of this cargo with
label-free technologies such as Raman and SPRi identified some
alternative avenues that can be explored. The onset of retrieving
data from the molecular content of EVs has also been explored in
the Cancer-ID program. A challenge is retrieving sufficient RNA
to represent the messenger RNA (mRNA) and long noncoding
RNA transcriptome. As a first step, various EV RNA isolation
kits were tested, and of the isolation kits tested, the Norgen
total RNA isolation protocol resulted in the highest amount of
RNA as determined by reverse transcription quantitative PCR
(RT-qPCR) of housekeeping and prostate-associated transcripts.
Although this Norgen protocol will also extract non-EV RNA
from urine, RNA yield and coverage by RNAseq are considered
of higher priority than purity for our EV-based biomarker efforts.
State-of-the-art integrated systems developed in the Cancer
ID Perspectief program come close to reliably detecting tdEVs
at clinically relevant concentrations at high throughput. Small
tdEVs (<1µm) can be isolated using functionalized anti-
EpCAM substrates and can be detected electrochemically in
a label-free manner (19). Next, sorting of tdEV populations
(as defined by fluorescence, by SPRi, electrochemically, or by
Raman spectroscopy) can be used to perform downstream
molecular analysis and reveal their genetic content that could
play a critical role in identifying the best therapeutic strategy for
cancer patients.
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